One trend in the pipeline that doesn't get enough attention: the move toward monthly (or even less frequent) dosing. Current GLP-1 agonists require weekly injections, but several companies are developing ultra-long-acting formulations.

The most advanced is ecnoglutide (formerly known as XW004), a GLP-1 receptor agonist engineered for monthly subcutaneous dosing. Early clinical data showed:

• Sustained GLP-1 receptor engagement over 4+ weeks from a single injection
• Preliminary weight loss data suggesting comparable efficacy to weekly GLP-1 RAs
• Acceptable tolerability profile (though GI events at injection were noted)

Other monthly approaches in development:

• Novo Nordisk: Investigating long-acting depot formulations of semaglutide
• Various biotechs: Exploring implantable devices, microparticle formulations, and antibody-drug conjugates for extended release

The obvious appeal: inject once a month instead of four times. Better adherence, fewer injection-site reactions, and potentially smoother pharmacokinetics without weekly peaks and troughs.

Monthly injections would be AMAZING. I actually forget my weekly tirzepatide injection about once every 6 weeks. I set reminders but life gets busy, I'm traveling, whatever. Having to remember only 12 times per year instead of 52 would help a lot with adherence.

My concern though — what happens if you get terrible nausea from a monthly dose? With weekly injections, you know the side effects will ease up in a day or two. With a monthly depot, are you stuck being nauseous for weeks? 😰

That's actually the biggest pharmacological challenge with monthly formulations. The slow-release kinetics should theoretically produce more stable drug levels (avoiding the peak-and-trough pattern of weekly dosing), which might actually reduce GI side effects since many of them correlate with the post-injection peak.

However, the flip side is exactly what you described: if a patient has an adverse reaction, you can't easily "un-inject" a depot formulation. With weekly dosing, you can skip a dose, reduce the dose, or wait it out for a few days. A monthly depot releases drug continuously for 4 weeks regardless.

This is likely why the clinical development programs for monthly GLP-1s will need very careful dose titration protocols and may require starting patients on weekly formulations first to confirm tolerability before switching to monthly.

Adherence data supports the argument for less frequent dosing. A meta-analysis of chronic disease medications showed:

• Daily dosing: ~50-60% adherence at 12 months
• Weekly dosing: ~60-70% adherence at 12 months
• Monthly dosing: ~70-80% adherence at 12 months

For GLP-1 specifically, real-world data shows that approximately 30-40% of patients prescribed weekly semaglutide or tirzepatide are non-persistent at 12 months (stopped filling prescriptions). Some of that is cost/access, but convenience and injection burden are significant factors.

If a monthly formulation could reduce the non-persistence rate by even 10 percentage points, the population-level health impact would be enormous.

Would monthly injections be more painful since you'd need a larger dose in one shot? I already find the weekly injection uncomfortable sometimes.